Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon Inc (ANNX) is a clinical-stage biopharmaceutical company developing complement-targeted therapies for neurological disorders. News coverage for Annexon typically focuses on clinical trial progress, regulatory interactions, financing activities, and scientific presentations demonstrating the company's complement inhibition platform.
For biotech investors tracking Annexon, news falls into several key categories. Clinical development updates announce enrollment milestones, trial completions, and data readouts for the company's programs in Huntington's disease, Alzheimer's disease, and geographic atrophy. Regulatory news covers interactions with agencies such as the FDA and EMA, including participation in product development programs and potential pathway discussions. Financing announcements detail public offerings, private placements, and other capital-raising activities that fund the company's research and development operations.
Scientific presentations at medical conferences provide insights into Annexon's complement-mediated neurodegeneration research and emerging clinical data. These presentations often reveal detailed results from ongoing studies before formal publication. Corporate developments include additions to scientific and medical leadership, particularly expertise in neurology and ophthalmology, which signal the company's strategic priorities and pipeline expansion.
Annexon also issues equity grant announcements for new employees, a routine practice for biotechnology companies that use stock-based compensation. While administrative in nature, these filings indicate hiring activity and organizational growth. Tracking this comprehensive news coverage helps investors understand Annexon's clinical progress, financial position, and strategic direction in the competitive neurodegeneration therapeutics landscape.
Annexon, a clinical-stage biopharmaceutical company, reported progress across its pipeline and first quarter 2022 financial results. With a broad portfolio of five candidates targeting complement-mediated disorders, Annexon anticipates eight clinical catalysts in 2022-2023. The lead candidate, ANX005, shows promise in treating Guillain-Barré Syndrome and Huntington's disease, demonstrating rapid clinical improvements. As of March 31, 2022, cash reserves totaled $206.7 million, sufficient to fund operations into 2024. However, the company reported a net loss of $35.4 million, reflecting increased expenses.
Annexon, Inc. (Nasdaq: ANNX) announced that CEO Douglas Love will participate in upcoming investor conferences: the BofA Securities 2022 Healthcare Conference on May 12, 2022, in Las Vegas, and the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami. The company specializes in developing complement-targeting medicines for autoimmune, neurodegenerative, and ophthalmic disorders. Webcasts of the events will be available on the company's website for 30 days post-conference. Annexon is advancing several clinical-stage candidates, including ANX005, ANX007, and ANX009.
Annexon completes enrollment in the Phase 2 ARCHER trial
Annexon (NASDAQ: ANNX) has successfully finished enrollment for its Phase 2 ARCHER trial, assessing ANX007 in patients with geographic atrophy (GA). Results on the primary endpoint are expected in the first half of 2023 after a 12-month treatment. GA affects approximately 1 million Americans, leading to potential blindness. The trial includes 270 patients and will examine both monthly and bi-monthly dosing. ANX007 previously showed promising results in a Phase 1b trial, demonstrating safety and full target engagement in the eye.
Annexon, Inc. (Nasdaq: ANNX) will have its president and CEO, Douglas Love, participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:45 p.m. ET. The event will be accessible via live webcast on the company's Investors page, with an archive available for 30 days post-event. Annexon focuses on developing unique complement medicines aimed at treating complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Their pipeline includes three clinical-stage candidates and innovative early-stage programs.
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced it will present preclinical data at the American Academy of Neurology Annual meeting from April 2-7, 2022. This data highlights their innovative approach to inhibiting C1q in complement-mediated diseases, which includes conditions like Guillain-Barré Syndrome and Huntington’s disease. Notable presentations include the efficacy of their therapy ANX005. The company aims to advance its clinical programs, leveraging its proprietary platform aimed at combating various complement-mediated disorders.
Annexon announced encouraging interim data from its Phase 2 study of ANX005 for Huntington’s Disease, showing positive tolerance and engagement at the six-month mark. Financially, the company reported a net loss of $37.4 million for Q4 2021, totaling $130.3 million for the year. As of December 31, 2021, Annexon had $242.7 million in cash, expected to fund operations into Q1 2024. Key milestones include further data releases for ANX005 and ANX009 in 2022, indicating a robust pipeline aimed at addressing complement-mediated diseases.
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that CEO Douglas Love will join the “Orphan CNS Panel” at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 2:10 p.m. ET. The panel focuses on complement-mediated conditions affecting the CNS. A live webcast will be available on Annexon's Investors page and will remain archived for 30 days post-event. Annexon is pioneering complement-targeting medicines aimed at autoimmune and neurodegenerative disorders, with a pipeline that includes three clinical-stage drug candidates and various early-stage programs.
Annexon, a clinical-stage biopharmaceutical company, announced the appointment of Bettina M. Cockroft, M.D., to its board of directors. Cockroft, who is currently the chief medical officer at Sangamo Therapeutics, brings nearly 20 years of experience in clinical organizations focused on neurodegenerative disorders. Annexon is advancing therapies for complement-mediated diseases, including Guillain–Barré Syndrome and Huntington’s Disease, with multiple data readouts expected over the next two years. This leadership change aims to enhance the company’s expertise in its novel complement-focused therapies.
Annexon (Nasdaq: ANNX) announced interim results from its ongoing Phase 2 trial of ANX005 for Huntington's disease (HD), showing encouraging safety and efficacy. The treatment demonstrated full target engagement of C1q in cerebrospinal fluid, with over 50% of evaluable patients maintaining clinical function. In patients with excess complement activity, 75% showed improvement in clinical measures. No serious adverse infections or deaths were reported. Full data is expected in Q2 2022, with plans for a Phase 3 trial pending results.
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that its CEO, Douglas Love, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 p.m. ET. The presentation will focus on their innovative complement medicines targeting autoimmune and neurodegenerative disorders. A live webcast will be available on their website, with a replay accessible for 30 days post-event.
Annexon's pipeline includes product candidates like ANX005, ANX007, and ANX009, designed to disrupt the C1q pathway.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
